Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Valeo Pharma In-Play, New HesperCo™ Immune System Support Scientifically Demonstrated

Shares of Valeo Pharma Inc. (CSE: VPH) (Frankfurt: VP2) poised for substantial upside revaluation to reflect the major ‘company –maker’ potential in HesperCo™ as the market figures out it is set to be the subject of Covid-19 clinical trial. Valeo will benefit...
Fredrick William | September 2, 2020 |

This Cannabis Co. is Mounting its COVID-Comeback

The COVID-19 coronavirus pandemic has forced a massive shift in businesses across the board and this is especially true for 1933 Industries (TGIF) ( CSE:TGIF , OTCQX: TGIFF , Forum ), who reported that during its Q3 2020 , its revenues were adversely impacted by closures...
Dave Jackson | July 24, 2020 |

Shares Rise as The Medicines Company Reports Positive Topline Results...

Shares Rise as The Medicines Company Reports Positive Topline Results from Two Phase 3 Cholesterol Trials The Medicines Company's shares are trading 8.5% higher today after the firm reported positive results from two phase 3 studies for inclisiran, one for familial hype...
Streetwise Reports | September 26, 2019 |

Assembly Biosciences Stock Sizzles Following Phase 2a Announcement and Buy Rating from Mizuho

Good news is piling up for this healthcare stock engaged in the treatment of hepatitis B as it trades at 5X its average volume with a 30% stock price gain over previous close. Assembly Biosciences Inc (ASMB:NASDAQ) announced in a press release on October 16, 2019, ...
Streetwise Reports | October 17, 2019 |

Small-Cap with Disruptive Real Estate Agent Platform Provides 'Blue-Sky' Potential

As the groundbreaking real-estate industry platform provides "disruption from the inside," the company moves to monetize its asset. Publicly traded small-cap RESAAS Services Inc. (RSS:TSX.V; RSASF:OTCQB) is changing the way real estate professionals do business. Its a...
Streetwise Reports | March 1, 2019 |

Analyst: Biopharma, Now Stronger Than Ever, Is an Ideal Takeout Target

An argument is made in a ROTH Capital Partners report for a potential imminent deal involving this drug maker. In an April 15 research note, ROTH Capital Partners analyst Yasmeen Rahimi reviewed the reasons why Galmed Pharmaceuticals Ltd. (GLMD:NASDAQ) is "high on the...
Streetwise Reports | April 18, 2019 |

Price Target Raised on Biopharma Ahead of Leukemia Trial Update

The expected data and their implications were addressed in a ROTH Capital Partners report. In an April 29 research report, analyst Jotin Marango reported that ROTH Capital Partners raised its price target on ArQule Inc. (ARQL:NASDAQ) to $10 per share in an...
Streetwise Reports | May 9, 2019 |

FDA Accepts NDA for Global Blood Therapeutics' Sickle Cell Drug; Shares Up 14%

Shares of Global Blood Therapeutics are trading more than 14% higher after the FDA accepted its New Drug Application filing for Voxelotor, a drug used in the treatment of sickle cell disease. Earlier today clinical-stage biopharmaceutical firm Global Blood Therapeuti...
Streetwise Reports | September 6, 2019 |

Biopharma Makes Licensing Deal for Therapeutic Rights in Japan

The company's reasons for the transaction and expected short-term, stock-moving events are provided in a ROTH Capital Partners report. In a Sept. 9 research note, ROTH Capital Partners analyst Yasmeen Rahimi reported that Eidos Therapeutics Inc. (EIDX:NASDAQ) agreed...
Streetwise Reports | September 12, 2019 |

Kiniksa Pharma Awarded FDA Breakthrough Therapy Status for Pericarditis Treatment Drug

Shares of Kiniksa Pharmaceuticals opened nearly 30% higher today after the firm reported that the FDA granted Breakthrough Therapy designation for Rilonacept for the treatment of recurrent pericarditis. This morning, Hamilton, Bermuda based biopharmaceutical company ...
Streetwise Reports | November 21, 2019 |
1 2